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Abstract In observational studies, selection of con-
founding variables for adjustment is often based on
observed baseline incomparability. The aim of this study
was to evaluate this selection strategy. We used clinical
data on the effects of inhaled long-acting beta-agonist
(LABA) use on the risk of mortality among patients with
obstructive pulmonary disease to illustrate the impact of
selection of confounding variables for adjustment based on
baseline comparisons. Among 2,394 asthma and COPD
patients included in the analyses, the LABA ever-users
were considerably older than never-users, but cardiovas-
cular co-morbidity was equally prevalent (19.9% vs.
19.9%). Adjustment for cardiovascular co-morbidity status
did not affect the crude risk ratio (RR) for mortality: crude
RR 1.19 (95% CI 0.93–1.51) versus RR 1.19 (95% CI
0.94–1.50) after adjustment for cardiovascular co-morbid-
ity. However, after adjustment for age (RR 0.95, 95% CI
0.76–1.19), additional adjustment for cardiovascular co-
morbidity status did affect the association between LABA
use and mortality (RR 1.01, 95% CI 0.80–1.26). Con-
founding variables should not be discarded based on bal-
anced distributions among exposure groups, because
residual confounding due to the omission of confounding
variables from the adjustment model can be relevant.
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Introduction
Selection of covariates for adjustment in randomized
trials is still frequently based on observed baseline
imbalances between the study groups [1], even though
this strategy is flawed and hence not recommended [2–4].
For example, relatively small imbalances (indicated by
large P values) of strong prognostic factors may still
result in bias, when omitting such variables from an
adjustment model [3].
In observational studies, the selection of covariates for
adjustment should not be based on baseline imbalances
either [5, 6]. Nevertheless, it is likely that this practice is
even more common in observational studies than in trials
[7], since adjustment for confounding is known to be an
important issue in observational designs. Similar to the
situation in trials, a variable that is a strong prognostic risk
factor of the outcome, yet weakly associated with exposure
may not be selected for adjustment, yet such omission may
result in confounding. Also, adjusting for variables that are
related to the exposure under study, yet are no true con-
founding variables, may actually introduce bias, rather than
remove it. Examples include so-called M-bias, Z-bias, and
adjustment for variables that are intermediates in the causal
chain [8, 9]. Hence, baseline imbalances should not guide
A. W. Hoes—On behalf of PROTECT WP2 (Framework for
pharmacoepidemiology studies, full list of collaborators in
Appendix). The PROTECT consortium (Pharmacoepidemiological
Research on Outcomes of Therapeutics by a European ConsorTium)
is a private–public partnership coordinated by the European
Medicines Agency (EMA).
R. H. H. Groenwold (&)  O. H. Klungel
Department of Pharmacoepidemiology and Clinical
Pharmacology, Utrecht Institute for Pharmaceutical Sciences,
University of Utrecht, Utrecht, P.O. Box 80082, 3508 TB,
The Netherlands
e-mail: r.h.h.groenwold@umcutrecht.nl
R. H. H. Groenwold  O. H. Klungel  D. E. Grobbee 
A. W. Hoes
Julius Center for Health Sciences and Primary Care, University
Medical Center Utrecht, Utrecht, The Netherlands
123
Eur J Epidemiol (2011) 26:589–593
DOI 10.1007/s10654-011-9606-1
selection of covariates for adjustment in observational
research.
Using observational data on the effects of long-acting
beta-agonist use on mortality risk in patients with
obstructive pulmonary disease, we here illustrate that even
a situation of ‘perfect’ balance of prognostic characteristics
between study groups should not result in omitting such
variables from being selected for adjustment for con-
founding. Before turning to this clinical example, we first
illustrate the invalidity of this strategy for selecting con-
founding variables using a numerical example on hypo-
thetical data.
Numerical example
Suppose an observational study was conducted among
20,000 subjects on the effects of a certain exposure. Two
variables (e.g., age and gender) were considered potential
confounding variables, because both were known risk
factors for the outcome of interest. Age (dichotomized at
e.g. 50 years), was imbalanced between the exposure
groups: of those exposed 75% were of old age, whereas
25% of those unexposed were of old age. Gender, however,
was equally distributed among the exposure groups, since
both groups included 50% females (Table 1).
The incidence of the outcome (e.g., mortality) among
those exposed was 13.5%, and among those unexposed
19.5%, resulting in an estimated risk ratio (RR) of 0.69.
Since gender was clearly balanced between the exposure
groups, stratification by gender was not expected to result
in a difference between the crude (i.e., unadjusted) RR and
gender-adjusted RR. Indeed, after adjustment for gender
the RR was equal to the crude RR (i.e., RR = 0.69).
Clearly, age was unevenly distributed among the expo-
sure groups. Stratification by age controlled for the con-
founding by age and resulted in a change in the risk ratio:
RR = 0.44. What is more, in these hypothetical data old
age and female gender were related, such that women
tended to be older (odds ratio = 6). However, by adjusting
(stratifying) for age, the gender distribution that was ini-
tially balanced between exposure groups changed: the
proportion females among exposed and unexposed subjects
of young age became 20 and 40%, respectively. Among
exposed and unexposed subjects of old age, the proportion
females became 60 and 80%, respectively. Hence, due to
the relation between age and gender, stratification by age
resulted in an uneven distribution of gender among the
exposure groups within age strata.
As a result, gender is likely to be considered a con-
founding variable within strata of young and old subjects.
Indeed, stratification by gender after stratification by age
resulted in another change in the risk ratio: RR = 0.50
(age- and gender-adjusted) versus RR = 0.44 (age-adjus-
ted RR). In Table 2, the cell counts of the two-by-two
tables for the exposure-outcome associations are given for
the different age-gender strata. By merging these tables, the
steps described above can be replicated in detail.
Clinical example
It has been suggested that inhaled beta-agonist therapy for
pulmonary obstructive diseases (i.e., asthma and COPD)
increases the risk of major cardiovascular events [10]. To
study the effects of ever versus never inhaled long-acting
beta agonist (LABA) use on all-cause mortality, we used a
sample from the Netherlands University Medical Center
Utrecht General Practitioner Research Network on the
period 1995–2005. Subjects were included in the cohort
when a diagnosis of asthma [ICPC code R96], or COPD
[ICPC code R95] was mentioned in the electronic database.
Ever versus never exposure to LABA was based on ATC
coding [ATC R03AC12, R03AC13, R03AK06, or
R03AK07]. The relation between LABA use and mortality
was analyzed using a Poisson regression model with robust
standard errors to estimate risk ratios [11]. Potential con-
founding variables were age, gender, and a diagnosis of
cardiovascular co-morbidity, because these are known risk
factors for myocardial infarction. For this example age was
arbitrarily dichotomized at 50 years: those older than
50 years, were considered ‘old’, the others ‘young’. Car-
diovascular co-morbidity was considered present when a
subject was treated with a cardiovascular drug (anti-
thrombotic drugs [ATC B01], cardiac therapy [ATC C01],
diuretics [ATC C03], beta-blockers [ATC C07], or agents
acting on the renin-angiotensin system [ATC C09]).
Among 2,394 asthma and COPD patients included in the
analyses, the LABA ever-users were considerably older
than never-users (Table 3). These groups did not differ,
however, with respect to cardiovascular co-morbidity sta-
tus (P = 0.99), or gender (P = 0.98). Consequently,
adjustment for cardiovascular co-morbidity status or gen-
der did not change the observed risk ratio (RR) for mor-
tality: unadjusted RR 1.19 (95% CI 0.93–1.51), RR 1.19
(95% CI 0.94–1.50) after adjustment for cardiovascular co-
morbidity status, and RR 1.19 (95% CI 0.94–1.51) after
adjustment for gender. However, adjustment for age
affected the RR considerably: RR 0.95 (95% CI
0.76–1.19). In this clinical example, old age and presence
Table 1 Characteristics of a hypothetical study population of 20,000
subjects
Exposed (n = 10,000) Unexposed (n = 10,000)
Female gender 5,000 (50%) 5,000 (50%)
Old age 7,500 (75%) 2,500 (25%)
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of cardiovascular co-morbidity were related (odds
ratio = 11). As a result, within age strata, cardiovascular
co-morbidity was no longer balanced between groups of
LABA users. For example, after stratification by age, the
proportions of cardiovascular co-morbidity among ever-
users and never-users of old age were 33.6 and 42.0%,
respectively (P = 0.002). Due to these imbalances, addi-
tional adjustment for cardiovascular co-morbidity status
indeed changed the risk ratio: RR 1.01 (95% CI 0.80–1.26).
The stratum-specific RRs were indeed approximately
similar (Table 4).
Since old age was also related to female gender (odds
ratio = 1.3), after stratification by age the groups of LABA
users were no longer comparable with respect to gender
either (e.g., proportions females among users among young
ever-users and never-users were 40.5 and 46.5%, respec-
tively (P = 0.04)). Consequently, additional adjustment
for gender resulted in another change in the risk ratio: RR
0.98 (95% CI 0.79–1.23).
Discussion
In observational studies, the selection of variables in a
model to adjust for confounding is often based on known
associations with the outcome under study (i.e., the vari-
ables are known risk factors for the outcome), and observed
associations with the exposure of interest [7]. Potential
confounding variables with an uneven distribution among
the exposure groups are then selected for (multivariable)
adjustment, whereas evenly distributed ones are omitted
from the adjustment model. Both the hypothetical and
clinical example show that this approach is incorrect and
can result in relevant residual confounding.
The observation that a variable is equally distributed
among exposure groups indicates that it is marginally (i.e.
unconditional on other variables) independent of the
exposure under study. If, however, two variables are mar-
ginally independent and both are related to a third variable,
they are dependent, conditional on that third variable [12].
Table 2 Association between
exposure and outcome within










Outcome Yes 100 450 Outcome Yes 50 600
No 1900 4050 No 450 2400









Outcome Yes 300 100 Outcome Yes 900 800
No 2700 400 No 3600 1200
RR = 0.50 RR = 0.50
Table 3 Distribution of patient characteristics by ever versus never long-acting beta-agonist (LABA) use
Patient characteristics Ever LABA-users (n = 795) Never LABA-users (n = 1599) P value
Old age (%) 402 (50.6) 628 (39.3) \0.001
Cardiovascular co-morbidity status 158 (19.9) 318 (19.9) 0.99
Female gender (%) 378 (47.5) 759 (47.5) 0.98
Data are presented as numbers (percentage)
 P values were calculated using Chi-square test
Table 4 Association between ever versus never long-acting beta-agonist (LABA) use and mortality, stratified by age and co-morbidity status
Stratum Number of subjects Number of ever LABA-users Mortality RR (95% CI)a
Young age, co-morbidity absent 1286 370 (28.8) 10 (0.8) 1.06 (0.28–4.08)
Young age, co-morbidity present 77 23 (29.9) 7 (9.1) 1.76 (0.43–7.25)
Old age, co-morbidity absent 631 267 (42.3) 110 (17.4) 1.10 (0.78–1.54)
Old age, co-morbidity present 399 135 (33.8) 126 (31.6) 0.88 (0.64–1.20)
Data are presented as numbers (percentage), unless indicated otherwise
a Risk ratio (95% confidence interval)
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This means that although exposure and gender (hypothet-
ical example) or LABA use and cardiovascular co-mor-
bidity status or gender (clinical example) were marginally
independent, they were dependent conditional on age,
because both were related to age.
The amount of (residual) confounding by the initially
balanced confounding variable after adjustment for age
alone likely depends on the strength of the association
between the two variables as well as the strength of the
association between the initially balanced confounding
variable and the outcome. In both examples these associ-
ations were substantial. Obviously, if age is not related to
the initially balanced confounding variable, stratification
by age will not result in an uneven distribution of the latter
variable within age strata, and hence no residual con-
founding due to that variable. In the clinical example, two
initially balanced confounding variables became imbal-
anced after stratification by age. In practice, the number of
initially balanced confounders could be even larger and
residual confounding due to omitting all these variables
from the adjustment model may become substantial,
especially when these variables are strong risk factors for
the outcome. Likewise, adjusting only for imbalanced
baseline covariates in a randomized trial may actually
induce bias by imbalancing other baseline covariates that
are strong risk factors for the outcome.
In textbooks on epidemiology, a confounding variable is
defined as a variable that is a risk factor for the outcome
under study and also related to the exposure of interest
[13, 14]. Furthermore, an intermediate to the causal chain
is by definition not a confounding variable. Thus, what is
considered a confounding variable depends on the outcome
of interest and exposure under study and hence the clinical
research question. However, it also depends on the stage of
analysis, since in the examples presented here, gender and
co-morbidity status did not confound the observed crude
association, but they were confounding variables for the
age-adjusted association.
Different strategies for selecting confounding variables
have been proposed. A frequently applied strategy is based
on some change-in-estimate criterion (e.g. 10% change in
OR), but variables may then be falsely identified as con-
founding variables due to non-collapsibility [15]. Statistical
tests to assess whether a certain variable is associated with
either the exposure, the outcome, or both, are typically
insensitive in small datasets, but raising the significance
level can reduce this problem [16]. However, even ‘per-
fect’ balance of prognostic characteristics among exposure
groups can result in confounding (as shown in our exam-
ples). Based on prior knowledge, common causes of both
exposure and outcome (or causes of either exposure or
outcome [17]) may be identified. Obviously, this relies on
available knowledge, but in any case established risk
factors for the outcome will be selected. Even if these
variables are not related to exposure, statistical power will
likely increase with adjustment for such risk factors [18].
Hence, selection of confounding variable for adjustment
starts with identifying risk factors for the outcome.
In conclusion, a risk factor for the outcome under study
that is evenly distributed among exposure groups can still
be a confounding variable. Hence, observed balance of
important prognostic variables among the exposure groups
in a baseline table should not result in omitting such
variables from the model to adjust for confounding.
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